medigraphic.com
ISSN 1527-3172 (Electronic)

2014, Number 3-4

<< Back Next >>

MEDICC Review 2014; 16 (3-4)

Immunoscintigraphy and radioimmunotherapy in Cuba: Experiences with labeled monoclonal antibodies for cancer diagnosis and treatment (1993–2013)

Peña QY, Perera PA, Batista CJF

Language: English
References: 49
Page: 55-60
PDF size: 150.46 Kb.


ABSTRACT

Introduction: The availability of monoclonal antibodies in Cuba has facilitated development and application of innovative techniques (immunoscintigraphy and radioimmunotherapy) for cancer diagnosis and treatment.
Objetive: Review immunoscintigraphy and radioimmunotherapy techniques and analyze their use in Cuba, based on the published literature. In this context, we describe the experience of Havana's Clinical Research Center with labeled monoclonal antibodies for cancer diagnosis and treatment during the period 1993–2013.
Evidence acquisition: Basic concepts concerning cancer and monoclonal antibodies were reviewed, as well as relevant international and Cuban data. Forty-nine documents were reviewed, among them 2 textbooks, 34 articles by Cuban authors and 13 by international authors. All works published by the Clinical Research Center from 1993 through 2013 were included. Bibliography was obtained from the library of the Clinical Research Center and Infomed, Cuba's national health telematics network, using the following keywords: monoclonal antibodies, immunoscintigraphy and radioimmunotherapy.
Results: Labeling the antibodies (ior t3, ior t1, ior cea 1, ior egf/r3, ior c5, h-R3, 14F7 and rituximab) with radioactive isotopes was a basic line of research in Cuba and has fostered their use as diagnostic and therapeutic tools. The studies conducted demonstrated the good sensitivity and diagnostic precision of immunoscintigraphy for detecting various types of tumors (head and neck, ovarian, colon, breast, lymphoma, brain).
Obtaining different radioimmune conjugates with radioactive isotopes such as 99mTc and 188Re made it possible to administer radioimmunotherapy to patients with several types of cancer (brain, lymphoma, breast). The objective of 60% of the clinical trials was to determine pharmacokinetics, internal dosimetry and adverse effects of monoclonal antibodies, as well as tumor response; there were few adverse effects, no damage to vital organs, and a positive tumor response in a substantial percentage of patients.
Conclusions: Cuba has experience with production and radiolabeling of monoclonal antibodies, which facilitates use of these agents. Studies in Cuba conducted by the Clinical Research Center over the past 20 years have yielded satisfactory results. Evidence obtained suggests promising potential of monoclonal antibodies and nuclear medicine, with immunoscintigraphy and radioimmunotherapy techniques providing alternatives for cancer diagnosis and treatment in Cuba.


REFERENCES

  1. National Statistics Division, Ministry of Public Health (CU). Anuario Estadístico 2012 [Internet]. Havana: Ministry of Public Health (CU); 2013 Apr [cited 2014 Apr 18]. Available from: http:// Spanish.

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin. 2012 Sep–Oct;62(5):283–98.

  3. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012 Mar 22;12(4):278–87.

  4. Cole SP, Campling BG, Atlaw T, Kozbor D, Roder JC. Human monoclonal antibodies. Mol Cell Biochem. 1984 Jun;62(2):109–20.

  5. Vilella R. Anticuerpos monoclonales. Realidades y perspectivas. Inmunología. 2004 Dec;23(4):374. Spanish.

  6. Pagana KD. Oncogammagrafía (Inmunogammagrafía). In: Pagana KD, Pagana TJ. Guía de pruebas diagnósticas y de laboratorio. 8th ed. Madrid: Elsevier; 2009 Apr 27. p. 726–28. Spanish.

  7. Oliva JP, Martínez A, Castro-Beiras JM. Carcinoma medular tiroideo. In: Castro-Beiras JM, editor. Avances en Medicina Nuclear y calidad 2002. p. 595–606. Spanish.

  8. Amaral H, Majlis A, Pruzzo R, Morales B, Gil C, Coudeu I, et al. La medicina nuclear más allá de las imágenes. Rev Med Nucl Alasbimn J. 2005 Jul;7(29). Spanish.

  9. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone: Results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood. 2005 Dec 1;106(12):3725–32.

  10. Connors JM. Radioimmunotherapy-hot new treatment for lymphoma. N Engl J Med. 2005 Feb 3;352(5):496–8.

  11. Weigert O, Illidge T, Hiddemann W, Dreyling M. Recommendations for the use of Ytrium-90 Ibritumomab Tiuxetan in Malignant Lymphoma. Cancer. 2006 Aug 15;107(4):686–95.

  12. Witzig T. Radioimmunotherapy for B-cell non- Hodgkin lymphoma. Best Prat Res Clin Haematol. 2006;19(4):655–68.

  13. Inwards DJ, Cilley JC, Winter JN. Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma. Best Pract Res Clin Haemtol. 2006;19(4):669–84.

  14. Casacó A, López G, García I, Rodríguez JA, Fernández R, Figueredo J, et al. Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma. Cancer Biol Ther. 2008 Mar;7(3):333–9.

  15. Dillman RO. Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies. Clin Exp Med. 2006 Mar;6(1):1–12.

  16. Sorenson JA, Phelps ME. Physics in nuclear medicine. Philadelphia: Saunders; 2003. p. 499–502.

  17. Faxas ME, Guerra ME, Álvarez A, Calderón C. Ensayo clínico fase I del anticuerpo monoclonal IOR-T1 en linfoma T: farmacocinética y respuesta inmune. Rev Cubana Med. 2003 Apr– Jun;42(2):33–8. Spanish.

  18. González GP, García IG, González JG, Sánchez LP, Mirabal MV, Marín CC, et. al. Phase I Clinical Trial of the 131I-Labeled Anticarcinoembryonic Antigen CIGB-M3 Multivalent Antibody Fragment. Cancer Biother Radiopharm. 2011 Jun;26(3):353–63.

  19. Perera A, Pérez C. Radiomarcaje de anticuerpos con tecnecio-99m. Rev Esp Med Nucl.1998;17(4):302–9. Spanish.

  20. Perera A, Pérez C, Torres MB, Hernández A, Heres FC, Moreira T, et al. A kit of human polyclonal IgG for the diagnosis of infectious processes. J Radioanal Nucl Chem. 1999 May;240(2):481–7.

  21. Ramos M, Rodriguez N, Oliva JP, Iznaga N, Perera A, Morales A, et al. ior egf/r3: A murine monoclonal antibody for diagnosis of epithelial tumors. J Radioanal Nucl Chem. 1999 Dec;240(12):499–503.

  22. Zayas F, Perera A, De la Peña L, Hernández T. Spanish.

  23. Sharma RK, Mishra AK, Iznaga N, Perera A, Mathew TL. 99mTc-labeling of humanized monoclonal antibody h-R3 using NH2-Lys-DTPA. Indian J Nucl Med. 2001;16(3):149–52.

  24. Perera A, Paredes M, Mishra AK, Iznaga N, Prats A, Hernández A. Marcaje indirecto de anticuerpos monoclonales empleando la N2-dietilentriamino- pentaacetil lisina amida como agente quelatante del 99mTc. Rev CENIC Ciencias Biológicas. 2006;37(4):248–54. Spanish.

  25. Perera A, Leyva R, Gamboa R, Alberdi L, Xiques A. Marcaje del anticuerpo monoclonal humanizado h-R3 con 188Re. Nucleus. 2003;33(1):64–8. Spanish.

  26. Cruz T, Oliva JP, Borrón M, Pimentel G. Impor- el antirreceptor del factor de crecimiento epidérmico en carcinomas de cabeza y cuello. Rev Cubana Oncol. 1999;15(3):160–4. Spanish.

  27. Ramos M, Rodríguez N, Oliva JP, Iznaga N, Perera A, Torres L, et al. Estudio del reconocimiento in vivo de los tumores de origen epitelial con los anticuerpos monoclonales ior c5, ior egf/r3 y hR3 humanizado, mediante la técnica de inmunogammagrafía. Nucleus. 2003;33(1):54–63. Spanish.

  28. Faxas ME, Barroso MC, Ortiz AR, García CA. Observaciones clínicas de la Fase I con el anticuerpo monoclonal IOR-T1 en pacientes con linfoma T cutáneo. Rev Cubana Oncol. 1999;15(1):36–42. Spanish.

  29. Ramón LG, Mustelier G, Ávila O, González L, Gutiérrez A, Hernández C. Tratamiento de la macroglobulinemia de Waldenstrom con R-CHOP. A propósito de un caso. Rev Hematol Mex. 2012;13(4):201–6. Spanish.

  30. Espinosa EE, Ramón LG, Izquierdo L, Ávila OM, Hernández C, Espinosa E. Rituximab: historia, farmacología y perspectivas. Rev Cubana Hematol Inmunol Hemoter. 2010;26(1):186–97. Spanish.

  31. Izquierdo L, Espinosa EE, Hernández C, Ramón LG, Ávila OM, Espinosa E. Rituximab en leucemia linfocítica crónica en recaída y anemia hemolítica autoinmune. Presentación de un caso. Rev Cubana Hematol Inmunol Hemoter. 2010;26(2):77–81. Spanish.

  32. Chávez R, Carnot J, de Castro R, Muñío J, Pérez G, Núñez A. Características clínicas y resultados terapéuticos de linfomas no Hodgkin de células grandes B mediastinal primarios. Rev Cubana Med. 2011;50(2):157–66. Spanish.

  33. Ramos M, Pintado AP, Mesa NR, Oliva JP, Izna- safety of 99mTc-labeled monoclonal antibody ior c5 in patients with colorectal and anal carcino- Biol Ther. 2007 Jan;6(1):22–9.

  34. Torres LA, Coca MA, Batista JF, Casacó A, López G, García I, et al. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidermal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas. Nucl Med Commun. 2008 Jan;29(1):66–75.

  35. Torres LA, Perera A, Batista JF, Hernández A, Crombet T, Ramos M, et al. Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin. Nucl Med Commun. 2005 Dec;26(12):1049–57.

  36. Crombet T, Torres L, Neninger E, Catalá M, Perera A, Torres O, et al. Pharmacological evaluation of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother. 2003 Mar–Apr;26(2):139–48.

  37. Iznaga N, Torres LA, Morales A, Ramos M, Alvarez I, Pérez N, et al. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumors of epithelial origin: I. biodistribution and dosimetry for radioinmunotherapy. J Nucl Med. 1998 Jan;39(1):15–23.

  38. Ramos M, Rodriguez N, Oliva JP, Iznaga N, Perera A, Morales A, et al. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part Nucl Med. 1999 May;40(5):768–75.

  39. Solano ME, Batista JF, Hernández A, Sánchez E, Pérez MG, Perera A, et al. Immunoscintigraphic diagnosis of ovarian cancer with Tc-99m labeled Med. 2003;2(1):30–6.

  40. Oliva JP, Valdés Z, Casacó A, Pimentel G, González J, Alvarez I, et al. Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m) Tc. Breast Cancer Res Treat. 2006 Mar;96(2):115–21.

  41. Leyva R, Perera A, Morín JA. Radiofármacos en inmunocentelleografía y radioinmunoterapia. Nucleus. 2012;(52):68–71. Spanish.

  42. Zayas F, Fraxedas R, Reyes L, Perera A, Mañalich R, Hernández L. Evaluación del 99mTc-ior t3 como radiotrazador del rechazo agudo del trasplante renal. Rev Esp Med Nucl. 1997;16(5):329–30. Spanish.

  43. Prada DM, Rosabal N, Molinero C, Gómez JA, Hernández IM, López AM, et al. Reumatoide: tratados con anticuerpo monoclonal Itolizumab. (T1h mAB), 2 años después de recibir tratamiento. Rev Cubana Reumatol. 2011;XIII(17):10–8. Spanish.

  44. Marrero LO, Álvarez R, Perera A, Yera J, Nicolás R, Hernández A, et al. Inmunografía con 99mTc- - nóstico de la sepsis osteoarticular. Rev Cubana Ortop Traumatol. 2003;17(1–2):7–13. Spanish.

  45. Nayak TK, Garmesteni K, Milenic DE, Brechbiel MW. PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab. J Nucl Med. 2012 Jan;53(1):113–20.

  46. Solomon M, Miranda N, Jorrín E, Chon I, Marinello JJ, Alert J, et al. Nimotuzumab in combination with radiotherapy in high grade glioma patients: A single institution experience. Cancer Biol Ther. 2014 May;15(5): 504–9.

  47. Registro Público Cubano de Ensayos Clínicos [Internet]. Havana: National Clinical Trials Coordinating Center (CU); c2014. Código del Registro Público: RPCEC00000016. Use of hR3 MAb and radiotherapy to treat patients with non small cells lung cancer (NSCLC) and brain metastasis; 2013 Nov 8 [cited 2014 Apr 18]; [about 2 p.]. Available from: http://registroclinico.sld.cu. Spanish.

  48. de mantenimiento de primera línea del linfoma folicular. Biodrugs. 2011;25(5):329–31. Spanish.

  49. Papi S, Martano L, Garaboldi L, Rossi A, Cremonesi M, Grana CM, et al. Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin). Nucl Med Biol. 2010 Jan;37(1):85–93.




2020     |     www.medigraphic.com